ChemoMetec - Public Comps and Valuation Multiples

ChemoMetec Overview

About ChemoMetec

ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.

Founded

1997

HQ

Employees

173

Website

chemometec.com

Sectors

Medical Devices
DeepTech
HealthTech

Financials

LTM Revenue $70.0M

LTM EBITDA $35.8M

EV

$1.2B

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

ChemoMetec Financials

ChemoMetec has a last 12-month revenue of $70.0M and a last 12-month EBITDA of $35.8M.

In the most recent fiscal year, ChemoMetec achieved revenue of $58.7M and an EBITDA of $27.9M.

ChemoMetec expects next 12-month revenue of XXX and NTM EBITDA of XXX

See ChemoMetec valuation multiples based on analyst estimates

ChemoMetec P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	$64.0M	$58.7M	XXX	XXX	XXX
Gross Profit	$55.3M	$56.9M	XXX	XXX	XXX
Gross Margin	86%	97%	XXX	XXX	XXX
EBITDA	$36.3M	$27.9M	XXX	XXX	XXX
EBITDA Margin	57%	48%	XXX	XXX	XXX
Net Profit	$23.0M	$25.7M	XXX	XXX	XXX
Net Margin	36%	44%	XXX	XXX	XXX
Net Debt	n/a	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

ChemoMetec Stock Performance

As of April 15, 2025, ChemoMetec's stock price is DKK 478 (or $69).

ChemoMetec has current market cap of DKK 8.3B (or $1.2B), and EV of DKK 8.1B (or $1.2B).

See ChemoMetec trading valuation data

ChemoMetec Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.2B	$1.2B	XXX	XXX	XXX	XXX	$1.51

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

ChemoMetec Valuation Multiples

As of April 15, 2025, ChemoMetec has market cap of $1.2B and EV of $1.2B.

ChemoMetec's trades at 16.6x LTM EV/Revenue multiple, and 32.4x LTM EBITDA.

Analysts estimate ChemoMetec's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for ChemoMetec and 10K+ public comps

ChemoMetec Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$1.2B	XXX	XXX	XXX
EV/Revenue	17.6x	XXX	XXX	XXX
EV/EBITDA	35.1x	XXX	XXX	XXX
P/E	50.2x	XXX	XXX	XXX
P/E/Growth	2.2x	XXX	XXX	XXX
EV/FCF	64.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get ChemoMetec Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

ChemoMetec Valuation Multiples

ChemoMetec's NTM/LTM revenue growth is 18%

ChemoMetec's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.2M for the same period.

Over next 12 months, ChemoMetec's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate ChemoMetec's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for ChemoMetec and other 10K+ public comps

ChemoMetec Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	-8%	XXX	XXX	XXX	XXX
EBITDA Margin	50%	XXX	XXX	XXX	XXX
EBITDA Growth	-23%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	68%	XXX	XXX	XXX	XXX
Revenue per Employee	$0.3M	XXX	XXX	XXX	XXX
Opex per Employee	$0.2M	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
Opex to Revenue	49%	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry